StockStory100d agoneutral
2 Large-Cap Stocks for Long-Term Investors and 1 Facing ChallengesNotícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
109last 24h
3127last 7d
511● bullish (7d)
313● bearish (7d)
227publishers
Simply Wall St.102d agoneutral
Gilead Sciences (GILD) Following Trodelvy Progress And A Fair Value DebatePharma Voice102d agoneutral
BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that.Benzinga102d agoneutral
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal TrialMT Newswires103d agoneutral
Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C TrialPharma Voice103d agoneutral
Kalshi is expanding online betting in drug R&D - unless detractors can stop it24/7 Wall St.104d agoneutral
FBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove ItBioPharma Dive109d agoneutral
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease studySimply Wall St.110d agoneutral
Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026Investor's Business Daily114d agoneutral
Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move.24/7 Wall St.116d agoneutral
Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?StockStory117d agoneutral
Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1